Consensus on pharmacological treatment of obesity in Latin America

Obes Rev. 2024 Apr;25(4):e13683. doi: 10.1111/obr.13683. Epub 2023 Dec 20.

Abstract

A panel of 10 experts in obesity from various Latin American countries held a Zoom meeting intending to reach a consensus on the use of anti-obesity medicines and make updated recommendations suitable for the Latin American population based on the available evidence. A questionnaire with 16 questions was developed using the Patient, Intervention, Comparison, Outcome (Result) methodology, which was iterated according to the modified Delphi methodology, and a consensus was reached with 80% or higher agreement. Failure to reach a consensus led to a second round of analysis with a rephrased question and the same rules for agreement. The recommendations were drafted based on the guidelines of the American College of Cardiology Foundation/American Heart Association Task Force on Practice. This panel of experts recommends drug therapy in patients with a body mass index of ≥30 or ≥27 kg/m2 plus at least one comorbidity, when lifestyle changes are not enough to achieve the weight loss objective; alternatively, lifestyle changes could be maintained while considering individual parameters. Algorithms for the use of long-term medications are suggested based on drugs that increase or decrease body weight, results, contraindications, and medications that are not recommended. The authors concluded that anti-obesity treatments should be individualized and multidisciplinary.

Keywords: Latin America; obesity; pharmacotherapy; weight management.

Publication types

  • Review

MeSH terms

  • Body Weight
  • Consensus
  • Humans
  • Latin America / epidemiology
  • Obesity* / drug therapy
  • Surveys and Questionnaires

Grants and funding